Study authors conducted a systematic review and meta-analysis to assess the efficacy of Janus kinase-inhibitors and Type I interferons as potential antiviral candidates for the treatment of COVID-19.
Researchers compared IL-1 and IL-6 inhibition vs standard management in hospitalized patients with COVID-19, respiratory insufficiency, and hyperinflammation.
The American College of Rheumatology developed clinical guidance for the use of COVID-19 vaccines in patients with rheumatic and musculoskeletal diseases.